Table 2.
apoM-induced RR at DCCT baseline and closeout stratified by disease status
| Measure | Disease progression (groups are not mutually exclusive) | |||
|---|---|---|---|---|
| Persistently normal (n = 329) | MA (n = 50) | CKD (n = 26) | MA and CKD (n = 19) | |
| Overall | — | 1.18 (0.97, 1.43); P = 0.09 | 1.55 (1.17, 2.06); P = 0.002 | 1.33 (0.98, 1.81); P = 0.065 |
| Baseline DCCT | — | 1.11 (0.84, 1.47); P = 0.46 | 1.44 (0.96, 2.17); P = 0.076 | 1.27 (0.74, 2.16); P = 0.38 |
| End of DCCT | — | 1.30 (1.01, 1.66); P = 0.038 | 1.69 (1.18, 2.44); P = 0.005 | 1.41 (0.92, 2.15); P = 0.11 |
RR are adjusted for DCCT treatment group assignment, baseline disease cohort, sex, comeasured eGFR, AER, and the use of any ACE/angiotensin receptor blocker medications prior to disease progression. RR are for a 1-standardized-unit increase in apoM and 95% CI compared with persistently normal. The standard unit is measured in terms of a z score.